Table 8.
Antimicrobial resistance of the strains of carbapenem-resistant Enterobacteriaceae (CRE) in patients with concomitant SARS-CoV-2 (COVID-19) that were included in a retrospective case–control study that aimed to identify the strains of CRE and the risk factors associated with acquiring these infections.
| Antibiotics | Antibiotic resistance tests in patients with COVID-19 and infection with CREn = 16 | Number of resistant bacteria |
|---|---|---|
| Carbapenem | 16 (100.00) | 16 (100.00) |
| Fluoroquinolone | 16 (100.00) | 16 (100.00) |
| Aminoglycoside | 16 (100.00) | 14 (87.50) |
| Colistin | 2 (12.50) | 1 (50.00) |
| Tigecycline | 1 (6.25) | 1 (100.00) |
| Imipenem-cilastatin-relebactam | 1 (6.25) | 0 (0.00) |
| Ceftazidim-avibactam | 1 (6.25) | 0 (0.00) |
| Ceftolozane-tazobactam | 1 (6.25) | 0 (0.00) |
Data presented as n of patients (%).